The TGF-β Superfamily As Potential Therapeutic Targets in Pancreatic Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Mar 19

PMID 38500662

Authors

Rachel R Tindall

Jennifer M Bailey-Lundberg

Yanna Cao

Tien C Ko

Affiliations

Soon will be listed here.

Abstract

The transforming growth factor (TGF)-β superfamily has important physiologic roles and is dysregulated in many pathologic processes, including pancreatic cancer. Pancreatic cancer is one of the most lethal cancer diagnoses, and current therapies are largely ineffective due to tumor resistance and late-stage diagnosis with poor prognosis. Recent efforts are focused on the potential of immunotherapies in improving therapeutic results for patients with pancreatic cancer, among which TGF-β has been identified as a promising target. This review focuses on the role of TGF-β in the diseased pancreas and pancreatic cancer. It also aims to summarize the current status of therapies targeting the TGF-β superfamily and postulate potential future directions in targeting the TGF-β signaling pathways.

Citing Articles

Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.

Demir T, Moloney C, Mahalingam D Cancers (Basel). 2025; 17(5).

PMID: 40075563 PMC: 11898821. DOI: 10.3390/cancers17050715.

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion.

Chen S, Kung H, Espinoza B, Washington I, Chen K, Wang J JCI Insight. 2024; 9(21).

PMID: 39298276 PMC: 11610749. DOI: 10.1172/jci.insight.182766.

Increased Gremlin1 Expression in Pancreatic Ductal Adenocarcinoma Promotes a Fibrogenic Stromal Microenvironment.

Tindall R, Faraoni E, Li J, Zhang Y, Ting S, Okeugo B Pancreas. 2024; 53(10):e808-e817.

PMID: 38829570 PMC: 11615151. DOI: 10.1097/MPA.0000000000002378.

References

Levy L, Hill C . Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol. 2005; 25(18):8108-25. PMC: 1234333. DOI: 10.1128/MCB.25.18.8108-8125.2005. View

Haake M, Haack B, Schafer T, Harter P, Mattavelli G, Eiring P . Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. Nat Commun. 2023; 14(1):4253. PMC: 10359308. DOI: 10.1038/s41467-023-39817-3. View

Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S . TGF-β - an excellent servant but a bad master. J Transl Med. 2012; 10:183. PMC: 3494542. DOI: 10.1186/1479-5876-10-183. View

Hahn S, Schutte M, Hoque A, Moskaluk C, DA COSTA L, Rozenblum E . DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996; 271(5247):350-3. DOI: 10.1126/science.271.5247.350. View

Ulloa L, Creemers J, Roy S, Liu S, Mason J, Tabibzadeh S . Lefty proteins exhibit unique processing and activate the MAPK pathway. J Biol Chem. 2001; 276(24):21387-96. DOI: 10.1074/jbc.M006933200. View

Wahl S, Hunt D, Wakefield L, McCartney-Francis N, Wahl L, Roberts A . Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A. 1987; 84(16):5788-92. PMC: 298948. DOI: 10.1073/pnas.84.16.5788. View

Wozney J, Rosen V, Celeste A, Mitsock L, Whitters M, Kriz R . Novel regulators of bone formation: molecular clones and activities. Science. 1988; 242(4885):1528-34. DOI: 10.1126/science.3201241. View

Shi Y, Hata A, Lo R, Massague J, Pavletich N . A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature. 1997; 388(6637):87-93. DOI: 10.1038/40431. View

Akhurst R, Derynck R . TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol. 2001; 11(11):S44-51. DOI: 10.1016/s0962-8924(01)02130-4. View

10.

Wischhusen J, Melero I, Fridman W . Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020; 11:951. PMC: 7248355. DOI: 10.3389/fimmu.2020.00951. View

11.

Zhang L, Zhou W, Velculescu V, Kern S, Hruban R, Hamilton S . Gene expression profiles in normal and cancer cells. Science. 1997; 276(5316):1268-72. DOI: 10.1126/science.276.5316.1268. View

12.

Tolcher A, Berlin J, Cosaert J, Kauh J, Chan E, Piha-Paul S . A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2017; 79(4):673-680. PMC: 5893148. DOI: 10.1007/s00280-017-3245-5. View

13.

Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R . Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2012; 31(1):23-9. DOI: 10.1200/JCO.2012.44.4869. View

14.

Bauskin A, Brown D, Junankar S, Rasiah K, Eggleton S, Hunter M . The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res. 2005; 65(6):2330-6. DOI: 10.1158/0008-5472.CAN-04-3827. View

15.

Peng D, Fu M, Wang M, Wei Y, Wei X . Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022; 21(1):104. PMC: 9033932. DOI: 10.1186/s12943-022-01569-x. View

16.

Attisano L, Wrana J . Signal transduction by the TGF-beta superfamily. Science. 2002; 296(5573):1646-7. DOI: 10.1126/science.1071809. View

17.

Katagiri T, Watabe T . Bone Morphogenetic Proteins. Cold Spring Harb Perspect Biol. 2016; 8(6). PMC: 4888821. DOI: 10.1101/cshperspect.a021899. View

18.

Lee J, Lee P, Yoon Y, Han B, Ko S, Park M . Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer. Biomed Pharmacother. 2023; 162:114716. DOI: 10.1016/j.biopha.2023.114716. View

19.

Lodyga M, Hinz B . TGF-β1 - A truly transforming growth factor in fibrosis and immunity. Semin Cell Dev Biol. 2019; 101:123-139. DOI: 10.1016/j.semcdb.2019.12.010. View

20.

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View